Is Irisin an Anticarcinogenic Peptide?

• Main Authors: Suat Tekin, Yavuz Erden, Suleyman Sandal, Bayram Yilmaz
• Format: Article
• Language: English
• Published: Society of TURAZ AKADEMI 2015-06-01
• Series: Medicine Science
• Subjects: Irisin; LNCaP; DU-145; PC3; cell viability
• Online Access: http://www.ejmanager.com/fulltextpdf.php?mno=171454

Prostate cancer is the most common type of cancer in males. There has been currently no therapy to cure various types of cancer, and hence, studies aiming to develop cancer treatment are important and have been ongoing. Irisin is a hormone, which regulates body weight and metabolism, including insulin resistance and is thought to have beneficial effects on the properties of antiobesytetic. It is known that obesity is a risk factor in the development of cancer and at the present time, the effects of peptides on cancer thay may reduce obesity have been investigated. This study was carried out to investigate whether there is a role of irisin on human prostate cancer cell viability. In the present study, 0.1, 1, 10 and 100 nM concentrations of irisin were separately applied to human prostate cancer cells with androgen receptor positive (LNCaP) and androgen receptor negative (DU-145, PC3). Effects of irisin on prostate cancer cells were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. At the end of study, all concentrations of irisin reduced the viability of all three prostate cell types, but only 10 and 100 nM concentrations of the irisin caused a significant decrease (p [Med-Science 2015; 4(2.000): 2172-80]